Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “EGFR Positive Non-Small Cell Lung Cancer”

281 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 281 results

Testing effectiveness (Phase 2)Study completedNCT03046992
What this trial is testing

Clinical Trial of YH25448 in Patients with EGFR Mutation Positive Advanced NSCLC

Who this might be right for
EGFR Gene Mutation
Yuhan Corporation 224
Early research (Phase 1)UnknownNCT05826483
What this trial is testing

Almonertinib in the First-line Treatment of Patients of NSCLC With Poor Performance Status

Who this might be right for
Malignant Tumor of LungPoor Performance Status
Guangzhou Institute of Respiratory Disease 20
Testing effectiveness (Phase 2)UnknownNCT02906163
What this trial is testing

First Line Bio-immunotherapy With Thymosin Alpha 1 in Patients With Sensitizing EGFR Mutation Positive Non Small Cell Lung Cancer Who Are Taking Standard of Care Therapy

Who this might be right for
EGFR Mutation Positive Non Small Cell Lung Cancer
SciClone Pharmaceuticals 188
Large-scale testing (Phase 3)UnknownNCT03008109
What this trial is testing

Endostar Plus EGFR-TKI（Epidermal Growth Factor Receptor-Tyrosine-Kinase Inhibitor） as a Treatment of EGFR Mutation-positive NSCLC

Who this might be right for
Advanced CancerLung Cancer, Nonsmall Cell
Zaiwen Fan 80
Testing effectiveness (Phase 2)Looking for participantsNCT07742332
What this trial is testing

Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC

Who this might be right for
EGFRNSCLC (Non-small Cell Lung Cancer)Locally Advanced Non-Small Cell Lung Cancer+2 more
Peng Zhang 160
Not applicableUnknownNCT03071705
What this trial is testing

Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma

Who this might be right for
Non-Small Cell AdenocarcinomaTyrosine Kinase MutationEGFR Gene Mutation
Instituto Nacional de Cancerologia de Mexico 120
Post-approval studies (Phase 4)Ended earlyNCT02299765
What this trial is testing

Intercalating and Maintenance Gefitinib in Combination With Chemotherapy for Advanced EGFR-mutant NSCLC

Who this might be right for
Non-small Cell Lung Cancer MetastaticEGFR Activating Mutation
Sichuan University 61
Testing effectiveness (Phase 2)UnknownNCT03382795
What this trial is testing

Retreatment With Epidermal Growth Factor Receptor(EGFR) Tyrosine Kinase Inhibitor in EGFR Mutation Positive Patients

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Korea University Guro Hospital 63
Testing effectiveness (Phase 2)Ended earlyNCT03784599
What this trial is testing

T-DM1 and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC

Who this might be right for
Carcinoma, Non-Small-Cell Lung
The Netherlands Cancer Institute 28
Testing effectiveness (Phase 2)UnknownNCT01410214
What this trial is testing

Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations

Who this might be right for
Non-small Cell Lung Cancer Stage IIIA
Chinese Lung Cancer Surgical Group 80
Testing effectiveness (Phase 2)UnknownNCT03749213
What this trial is testing

Icotinib as Neoadjuvant Therapy in EGFR-mutant Stage ⅢA-N2 Non-small Cell Lung Cancer

Who this might be right for
EGF-R Positive Non-Small Cell Lung Cancer
Betta Pharmaceuticals Co., Ltd. 36
Testing effectiveness (Phase 2)Study completedNCT02289833
What this trial is testing

Trastuzumab Emtansine in Participants With Human Epidermal Growth Factor Receptor (HER)2 Immunohistochemistry (IHC)-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-Small Cell Lung Cancer
Hoffmann-La Roche 49
Testing effectiveness (Phase 2)Study completedNCT01565538
What this trial is testing

Erlotinib Versus Pemetrexed as Second-Line Therapy in Treating Patients With Advanced Lung Adenocarcinoma

Who this might be right for
Lung Cancer
Si-Yu Wang 123
Testing effectiveness (Phase 2)Study completedNCT01982955
What this trial is testing

Tepotinib With Gefitinib in Participants With Locally Advanced or Metastatic NSCLC (INSIGHT)

Who this might be right for
Non-small Cell Lung Cancer
Merck KGaA, Darmstadt, Germany 88
Not applicableStudy completedNCT04105153
What this trial is testing

Real-world Analysis of Workup at Disease Progression and Implementation of Osimertinib for EGFR+ NSCLC

Who this might be right for
EGFR Positive Non-small Cell Lung Cancer
Thoraxklinik-Heidelberg gGmbH 400
Large-scale testing (Phase 3)Study completedNCT04248829
What this trial is testing

Clinical Trial of YH25448(Lazertinib) as the First-line Treatment in Patients With EGFR Mutation Positive Locally Advanced or Metastatic NSCLC (LASER301)

Who this might be right for
Non-Small Cell Lung Cancer
Yuhan Corporation 393
Not applicableEnded earlyNCT02932345
What this trial is testing

Gefitinib Long-term Survivor Study

Who this might be right for
EGFR Mutation Positive Advanced Non-small-cell Lung Cancer
AstraZeneca 59
Early research (Phase 1)Ended earlyNCT03054038
What this trial is testing

Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Carcinoma
Vanderbilt-Ingram Cancer Center 22
Testing effectiveness (Phase 2)Ended earlyNCT01953926
What this trial is testing

Basket Study of Neratinib in Participants With Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations

Who this might be right for
Solid Tumors Harboring Somatic HER2 or EGFR Exon 18 Mutations
Puma Biotechnology, Inc. 582
Testing effectiveness (Phase 2)Looking for participantsNCT06631989
What this trial is testing

Assess the Efficacy and Safety of WSD0922-FU in Patients With EGFRm+ Advanced Non-small Cell Lung Cancer

Who this might be right for
EGFR Mutation Positive Advanced Non-Small Cell Lung Cancer
Wayshine Biopharm, Inc. 100
Next Page